Home › Compare › IVIXF vs QYLD

IVIXF vs QYLD: Dividend Comparison 2026

IVIXF yields 5420.05% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IVIXF wins by $136326195118802.20M in total portfolio value
10 years
IVIXF
IVIXF
● Live price
5420.05%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$136326195118802.23M
Annual income
$131,551,666,493,773,860,000.00
Full IVIXF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — IVIXF vs QYLD

📍 IVIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIVIXFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IVIXF + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IVIXF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IVIXF
Annual income on $10K today (after 15% tax)
$460,704.61/yr
After 10yr DRIP, annual income (after tax)
$111,818,916,519,707,770,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, IVIXF beats the other by $111,818,916,519,707,770,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IVIXF + QYLD for your $10,000?

IVIXF: 50%QYLD: 50%
100% QYLD50/50100% IVIXF
Portfolio after 10yr
$68163097559401.13M
Annual income
$65,775,833,246,886,930,000.00/yr
Blended yield
96.50%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IVIXF buys
0
QYLD buys
1
PoliticianChamberTickerTypeAmountDate
Tim Moore🏢 House$QYLD▼ Sell$15,001 - $50,0002025-05-02
Tim Moore🏢 House$QYLD▲ Buy$15,001 - $50,0002025-04-07
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002022-11-14
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002020-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIVIXFQYLD
Forward yield5420.05% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$136326195118802.23M ✓$25.4K
Annual income after 10y$131,551,666,493,773,860,000.00 ✓$5,659.31
Total dividends collected$136003983287005.17M ✓$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: IVIXF vs QYLD ($10,000, DRIP)

YearIVIXF PortfolioIVIXF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$552,705$542,005.42$10,352$1,192.36+$542.4K → IVIXF
2$28,588,529$27,997,133.96$10,830$1,347.57+$28.58M → IVIXF
3$1,383,995,048$1,353,405,322.61$11,460$1,539.07+$1383.98M → IVIXF
4$62,714,057,337$61,233,182,635.19$12,275$1,777.84+$62714.05M → IVIXF
5$2,660,288,543,813$2,593,184,502,462.66$13,323$2,078.95+$2660288.53M → IVIXF
6$105,651,330,702,723$102,804,821,960,842.73$14,667$2,463.34+$105651330.69M → IVIXF
7$3,928,761,972,612,137$3,815,715,048,760,222.50$16,396$2,960.57+$3928761972.60M → IVIXF
8$136,812,745,737,264,320$132,608,970,426,569,340.00$18,631$3,612.97+$136812745737.25M → IVIXF
9$4,462,176,285,073,260,500$4,315,786,647,134,387,700.00$21,548$4,482.15+$4462176285073.24M → IVIXF
10$136,326,195,118,802,240,000$131,551,666,493,773,860,000.00$25,398$5,659.31+$136326195118802.20M → IVIXF

IVIXF vs QYLD: Complete Analysis 2026

IVIXF — Stock

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.

Full IVIXF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this IVIXF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IVIXF vs SCHDIVIXF vs JEPIIVIXF vs OIVIXF vs KOIVIXF vs MAINIVIXF vs XYLDIVIXF vs JEPQIVIXF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.